Galectin-1 in Stable Liver Transplant Recipients
Autor: | M. Arias, Marcos López-Hoyos, Susana Llerena, Miguel Garcia, Javier Crespo, Emilio Fábrega, Paula Iruzubieta, Angela Puente, F. Jurado, D. San Segundo, Fernando Casafont |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Graft Rejection Male Galectin 1 medicine.medical_treatment Liver transplantation Immune tolerance Immune Tolerance medicine Humans Aged Transplantation Human liver business.industry Healthy subjects Case-control study Middle Aged Liver Transplantation Up-Regulation Case-Control Studies Galectin-1 Immunology Female Surgery Solid organ transplantation business Biomarkers Immunosuppressive Agents |
Zdroj: | Transplantation Proceedings. 47:93-96 |
ISSN: | 0041-1345 |
DOI: | 10.1016/j.transproceed.2014.12.001 |
Popis: | Introduction The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients. Methods Serum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group. Results The concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group. Conclusions These preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation. |
Databáze: | OpenAIRE |
Externí odkaz: |